US4587249A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
Assignee: Analgesic Associates
•
Filing: 1984-08-22
•
Granted: 1986-05-06
•
Expires: 2004-08-22
Abstract
Abstract Novel analgesic and anti-inflammatory compositions of matter for use in eliciting an analgesic or anti-inflammatory response, said compositions comprising caffeine together with a selected non-narcotic analgesic/nonsteroidal anti-inflammatory drug or a selected narcotic analgesic, or both, are disclosed. When used in combination with the selected drugs, caffeine enhances the analgesic or anti-inflammatory response and also hastens its onset.
Inventors
- 👤 Abraham Sunshine
- 👤 Eugene M. Laska
- 👤 Carole E. Siegel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 09:43
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K31/54; A61K31/60; A61K45/00; A61K45/06
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
73 words
A method for eliciting an onset hastened and enhanced analgesic or anti-inflammatory response in a mammal, comprising administering to said mammal a pharmaceutical composition comprising: (a) an analgesically and anti-inflammatorily effective amount of a non-steroidal anti-inflammatory drug comprising an oxicam derivative or a pharmaceutically acceptable salt thereof selected from piroxicam, sudoxicam, isoxicam and [4-hydroxyl-1,2-benzothiazine-1,1-dioxide-4-(N-phenyl)-carboxamide]; and (b) an amount of caffeine sufficient to hasten the onset of and enhance the analgesic or anti-inflammatory response.
Claim 2
Independent Claim
73 words
A method for eliciting an onset hastened and enhanced analgesic or anti-inflammatory response in a mammal, comprising administering to said mammal a pharmaceutical composition comprising: (a) an analgesically and anti-inflammatorily effective amount of a non-steroidal anti-inflammatory drug comprising an oxicam derivative or a pharmaceutically acceptable salt thereof selected from piroxicam, sudoxicam, isoxicam and [4-hydroxyl-1,2-benzothiazine-1,1-dioxide-4-(N-phenyl)-carboxamide]; and (b) an amount of caffeine sufficient to hasten the onset of and enhance the analgesic or anti-inflammatory response.
Claim 3
Dependent Claim
14 words
A method according to claim 1 wherein in the non-steroidal anti-inflammatory drug is piroxicam.
Claim 4
Dependent Claim
13 words
A method according to claim 1, wherein the non-steroidal anti-inflammatory drug is sudoxicam.
Claim 5
Dependent Claim
13 words
A method according to claim 1, wherein the non-steriodal anti-inflammatory drug is isoxicam.
Claim 6
Dependent Claim
13 words
A method according to claim 1, wherein the non-steriodal anti-inflammatory drug is [4-hydroxyl-1,2-benzothiazine-1,1-dioxide-4-(N-phenyl)-carboxamide].
Claim 7
Dependent Claim
16 words
A method according to claim 1, comprising from about 60 mg and about 200 mg caffeine.
Claim 8
Dependent Claim
16 words
A method according to claim 6, comprising from about 65 mg to about 150 mg caffeine.
Claim 9
Dependent Claim
34 words
A method according to claim 2, comprising from about 25 mg to about 600 mg of said oxicam derivative or pharmaceutically acceptable salt thereof and from about 60 mg to about 200 mg caffeine.
Claim 10
Dependent Claim
71 words
A pharmaceutical composition of matter for use in eliciting an onset hastened or enhanced analgesic or anti-inflammatory response in a mammal, said composition comprising: (a) an analgesically and anti-inflammatorily effective amount of a non-steriodal anti-inflammatory drug comprising an oxicam derivative or pharmaceutically acceptable salt thereof selected from piroxicam, sudoxicam, isoxicam and [4-hydroxyl-1,2-benzothiazine-1,1-dioxide-4-(N-phenyl)-carboxamide]; and (b) an amount of caffeine sufficient to hasten the onset of and enhance the analgesic or anti-inflammatory response.
Claim 11
Dependent Claim
71 words
A pharmaceutical composition of matter for use in eliciting an onset hastened or enhanced analgesic or anti-inflammatory response in a mammal, said composition comprising: (a) an analgesically and anti-inflammatorily effective amount of a non-steriodal anti-inflammatory drug comprising an oxicam derivative or pharmaceutically acceptable salt thereof selected from piroxicam, sudoxicam, isoxicam and [4-hydroxyl-1,2-benzothiazine-1,1-dioxide-4-(N-phenyl)-carboxamide]; and (b) an amount of caffeine sufficient to hasten the onset of and enhance the analgesic or anti-inflammatory response.
Claim 12
Dependent Claim
14 words
A pharmaceutical composition according to claim 9, wherein the non-steroidal anti-inflammatory drug is piroxicam.
Claim 13
Dependent Claim
14 words
A pharmaceutical composition according to claim 9, wherein the non-steriodal anti-inflammatory drug is sudoxicam.
Claim 14
Dependent Claim
14 words
A pharmaceutical composition according to claim 9, wherein the non-steriodal anti-inflammatory drug is isoxicam.
Claim 15
Dependent Claim
14 words
A pharmaceutical composition according to claim 9, wherein the non-steroidal anti-inflammatory drug is [4-hydroxyl-1,2-benzothiazine-1,1-dioxide-4-(N-phenyl)-carboxamide].
Claim 16
Dependent Claim
17 words
A pharmaceutical composition according to claim 9, comprising from about 60 mg to about 200 mg caffeine.
Claim 17
Dependent Claim
17 words
A pharmaceutical composition according to claim 9, comprising from about 65 mg to about 150 mg caffeine.
Claim 18
Dependent Claim
35 words
A pharmaceutical composition according to claim 9, comprising from about 25 mg to about 600 mg of said oxicam derivative or pharmaceutically acceptable salt thereof and from about 60 mg to about 200 mg caffeine.
Claim 19
Dependent Claim
14 words
A pharmaceutical composition according to claim 9, further comprising a pharmaceutically acceptable inert carrier.
Claim 20
Dependent Claim
14 words
A pharmaceutical composition according to claim 17, said composition being adapted for oral administration.
Claim 21
Dependent Claim
16 words
A pharmaceutical composition according to claim 18, said composition being formulated as a tablet or capsule.
Claim 22
Dependent Claim
15 words
A pharmaceutical composition according to claim 9, wherein said composition is in sustained release form.
Claim 23
Dependent Claim
31 words
A pharmaceutical composition according to claim 10, comprising from about 10 mg to about 20 mg piroxicam, and from about 65 mg to about 150 mg caffeine in sustained release form.
Claim 24
Dependent Claim
14 words
A pharmaceutical composition according to claim 19, said composition being adapted for rectal administration.
Claim 25
Dependent Claim
14 words
A pharmaceutical composition according to claim 22, said composition being formulated as a suppository.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-05-05 | 1989-11-04 | 1990-05-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-05-05 | 1993-11-04 | 1994-05-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-05-05 | 1997-11-04 | 1998-05-06 | $7700.00 | Window Closed / Lapsed |